References
- Modell B., Beck J. Ann. N. Y. Acad. Sci. 1974; 232: 201–210
- Gutteridge J. M. C., Rowley D. A., Halliwell B. Biochem. J. 1981; 199: 263–265
- Walling C. Oxidases and Related Redox Systems, T. E. King, H. S. Mason, M. Morrison. Pergamon Press, Oxford 1982; 85–97
- Haber F., Weiss J. Proc. Roy. Soc. London Ser. A. 1934; 147: 332–351
- Jacobs A. British Journal of Haematology 1976; 34: 1–4
- Rachmilewitz E. A., Lubin B. H., Shohet S. B. Blood 1976; 47: 495–505
- Cook J., Watson S. S., Simpson K. M., Lipschitz D. A., Skikne B. S. Blood 1984; 64: 721–726
- Nienhuis A. W., Griffith P., Strawczynski H., Henry W., Borer J., Leon M., Anderson F. W. Annals. N. Y. Acad. Sci., 344: 384–396
- Modell B., Berdoukas V. The Clinical Approach to Thalassaemia. Grune and Stratton. 1984; 222–223
- Harley J. D., Mauer A. M. Blood 1960; 16: 1722–1735
- Beutler E., Duron O., Kelly B. M. J. Lab. Clin. Med. 1963; 61: 882–888
- Brownlee N. R., Huttner J. J., Panganamala R. V., Cornwell D. G. Journal of Lipid Research 1977; 18: 635–644
- Kontoghiorghes G. The Design of Orally Active Iron Chelators for the Treatment of Thalassaemia. PhD. Thesis, Essex University. 1982